In vitro antitumor reactivity of mononuclear leukocytes from cancer patients receiving immunotherapy with BCG

G. M. Mavligit, Evan M Hersh

Research output: Contribution to journalArticle

Abstract

Mononuclear cell-mediated cytotoxicity (MCMC) against cultured tumor target cells was studied sequentially in melanoma and breast cancer patients before and during BCG administration. MCMC showed temporary fluctuations. In patients with locally advanced melanoma and carcinoma of the breast after tumor load reduction, the administration of BCG may increase the MCMC. This did not always correlate with a favorable clinical course. Potentiating serum factors appeared in 50% of these patients during BCG therapy, while blocking factors were rare. Neither correlated with prognosis. In patients with disseminated melanoma receiving chemoimmunotherapy, increases in MCMC may be related to clinical course. Blocking serum factors frequently developed in this group of patients and potentiating factors were rare. Neither correlated with the clinical course. Significant MCMC among normal donors and the apparent lack of specificity suggest a common non-specific (? natural) cellular reactivity against cultured tumor target cells.

Original languageEnglish (US)
Pages (from-to)115-126
Number of pages12
JournalMedical and Pediatric Oncology
VolumeVol. 5
StatePublished - 1978
Externally publishedYes

Fingerprint

Mononuclear Leukocytes
Mycobacterium bovis
Immunotherapy
Cultured Tumor Cells
Melanoma
Neoplasms
Breast Neoplasms
Tumor Burden
Serum
In Vitro Techniques
Tissue Donors
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

In vitro antitumor reactivity of mononuclear leukocytes from cancer patients receiving immunotherapy with BCG. / Mavligit, G. M.; Hersh, Evan M.

In: Medical and Pediatric Oncology, Vol. Vol. 5, 1978, p. 115-126.

Research output: Contribution to journalArticle

@article{827aa9b81a054edd931784d884d0d1f7,
title = "In vitro antitumor reactivity of mononuclear leukocytes from cancer patients receiving immunotherapy with BCG",
abstract = "Mononuclear cell-mediated cytotoxicity (MCMC) against cultured tumor target cells was studied sequentially in melanoma and breast cancer patients before and during BCG administration. MCMC showed temporary fluctuations. In patients with locally advanced melanoma and carcinoma of the breast after tumor load reduction, the administration of BCG may increase the MCMC. This did not always correlate with a favorable clinical course. Potentiating serum factors appeared in 50{\%} of these patients during BCG therapy, while blocking factors were rare. Neither correlated with prognosis. In patients with disseminated melanoma receiving chemoimmunotherapy, increases in MCMC may be related to clinical course. Blocking serum factors frequently developed in this group of patients and potentiating factors were rare. Neither correlated with the clinical course. Significant MCMC among normal donors and the apparent lack of specificity suggest a common non-specific (? natural) cellular reactivity against cultured tumor target cells.",
author = "Mavligit, {G. M.} and Hersh, {Evan M}",
year = "1978",
language = "English (US)",
volume = "Vol. 5",
pages = "115--126",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - In vitro antitumor reactivity of mononuclear leukocytes from cancer patients receiving immunotherapy with BCG

AU - Mavligit, G. M.

AU - Hersh, Evan M

PY - 1978

Y1 - 1978

N2 - Mononuclear cell-mediated cytotoxicity (MCMC) against cultured tumor target cells was studied sequentially in melanoma and breast cancer patients before and during BCG administration. MCMC showed temporary fluctuations. In patients with locally advanced melanoma and carcinoma of the breast after tumor load reduction, the administration of BCG may increase the MCMC. This did not always correlate with a favorable clinical course. Potentiating serum factors appeared in 50% of these patients during BCG therapy, while blocking factors were rare. Neither correlated with prognosis. In patients with disseminated melanoma receiving chemoimmunotherapy, increases in MCMC may be related to clinical course. Blocking serum factors frequently developed in this group of patients and potentiating factors were rare. Neither correlated with the clinical course. Significant MCMC among normal donors and the apparent lack of specificity suggest a common non-specific (? natural) cellular reactivity against cultured tumor target cells.

AB - Mononuclear cell-mediated cytotoxicity (MCMC) against cultured tumor target cells was studied sequentially in melanoma and breast cancer patients before and during BCG administration. MCMC showed temporary fluctuations. In patients with locally advanced melanoma and carcinoma of the breast after tumor load reduction, the administration of BCG may increase the MCMC. This did not always correlate with a favorable clinical course. Potentiating serum factors appeared in 50% of these patients during BCG therapy, while blocking factors were rare. Neither correlated with prognosis. In patients with disseminated melanoma receiving chemoimmunotherapy, increases in MCMC may be related to clinical course. Blocking serum factors frequently developed in this group of patients and potentiating factors were rare. Neither correlated with the clinical course. Significant MCMC among normal donors and the apparent lack of specificity suggest a common non-specific (? natural) cellular reactivity against cultured tumor target cells.

UR - http://www.scopus.com/inward/record.url?scp=0018196670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018196670&partnerID=8YFLogxK

M3 - Article

C2 - 370532

AN - SCOPUS:0018196670

VL - Vol. 5

SP - 115

EP - 126

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

ER -